Algorithme Pharma Announces a Strategic Appointment

LAVAL, Canada, May 12, 2010 - Doug Peel, Executive Chairman of the Board of Directors of Algorithme
Pharma, is pleased to announce the appointment of Christopher Perkin as the
company's President and Chief Executive Officer. Mr. Perkin will officially
join the company on May 31st.

This important appointment confirms Algorithme Pharma's commitment to
the development of innovative strategies to better serve its clients and
business partners. It also reflects the company's on- going efforts to
become a world leader in clinical research and bioanalysis.

A native of England with a solid scientific background, Christopher
Perkin is a seasoned executive and recognized leader with more than 30
years' experience in pharmaceutical development and business strategy.
After holding several key positions at Huntingdon Research Center and
Beecham Pharmaceuticals, Mr. Perkin joined the Charles River Laboratories
in Senneville, Quebec, Canada, where he rose through the ranks to
Corporate Senior Vice President - Global Preclinical Services with
responsibility for operations in Asia and North America.

"Mr. Perkin is a highly talented individual with world-class
experience in our industry, and I am confident he wil create a dynamic
environment with a renewed business focus that wil reinforce our
industry-leading position and assure our status as a key international
partner of pharmaceutical companies," said Doug Peel, Executive Chairman of
the Board of Algorithme Pharma Holdings Inc.

About Algorithme Pharma

As a major global player in clinical research and bioanalysis,
Algorithme Pharma provides a wide range of services for bioequivalence and
early stage development (Phase I/IIa) studies to the pharmaceutical, and
biotechnology industries. In addition to its multi-unit clinical facilities
in Canada and the United Kingdom (more than 250 beds) and with its new
dedicated Montreal state-of-the-art facility for Phase I clinical studies,
Algorithme Pharma offers different services including protocol designs,
CTD/ICH clinical reports, data management, biostatistics, quality assurance
and regulatory affairs. Successfully audited by the US FDA, Canada TPD,
Brazil ANVISA, France AFSSAPS, UK MHRA and Austria AGES regulatory
authorities, Algorithme Pharma conducts over 275 clinical trials per year.

For further information: Mme Marie-Claude Boisvert, Vice President,
Kilmer Capital Partners, +1-(514)-973-6077; www.algopharm.com

For further information: Mme Marie-Claude Boisvert, Vice President, KilmerCapital Partners, +1-(514)-973-6077; www.algopharm.com